Key clinical point: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves the survival of patients with colorectal cancer (CRC) and peritoneal metastasis.
Major finding: The CRS plus HIPEC vs control group had a longer overall survival (hazard ratio 0.53; P < .00001).
Study details: This was a meta-analysis of 10 studies (3 randomized controlled trials and 7 cohort studies) including 3200 patients with CRC and peritoneal metastasis who were assigned to the CRS plus HIPEC (n = 788) or control (n = 2412) group.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Li J et al. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: A systematic review and meta-analysis. World J Surg Oncol. 2022;20:200 (Jun 14). Doi: 10.1186/s12957-022-02666-3.